18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

“…In cases with atelectasis, PET helped to demarcate the border between tumor and collapsed lung, allowing a smaller volume of lung to be treated [85] ( Figure 1). …”

A Prospective Study to Determine Inter-observer Variability of Gross Tumor Volume with [18F] Fludeoxyglucose-PET/CT Compared to CT Alone in Stage III Non-Small Cell Lung Cancer Using Three-Dimensional Analysis

“…Previously reported small studies have shown that FDG-PET/CT modifies the GTV defined by CT [11,[14][15][16][17][18][19][20][21][22][23][24]. Most of these studies determined only the interobserver variability of target volumes for changes in size, not position and overlap.…”

Feasibility of Shrinking Field Radiation Therapy through 18F-FDG PET/CT after 40 Gy for Stage III Non-Small Cell Lung Cancers

“…There is a strong case for the routine use of FDG-PET in radiation therapy planning for NSCLC, and the two most important and consistent reasons for applying PET in target volumes in NSCLC were listed (MacManus et al, 2009). On one hand, FDG-PET significantly changed lymph node staging in the thorax, usually by showing more positive nodes than CT. On the other hand, in cases with atelectasis, PET helped to demarcate the border between tumor and collapsed lung, allowing a smaller volume of lung to be treated (Nestle et al, 1999). On the basis of high FDG-avidity, the target volumes for the initial and after 40 Gy irradiation were delineated in the fused PET/CT images, we expected to verify that shrinking field technique after 4 weeks' radiation therapy would be feasible to reduce doses to normal tissues.…”